Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease - PubMed (original) (raw)
Clinical Trial
. 2000 Sep 19;102(12):1388-93.
doi: 10.1161/01.cir.102.12.1388.
Affiliations
- PMID: 10993857
- DOI: 10.1161/01.cir.102.12.1388
Clinical Trial
Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease
C G Brilla et al. Circulation. 2000.
Abstract
Background: In arterial hypertension, left ventricular hypertrophy (LVH) includes myocyte hypertrophy and fibrosis, which leads to LV diastolic dysfunction and, finally, heart failure. In spontaneously hypertensive rats, myocardial fibrosis was regressed and LV diastolic function was improved by treatment with the angiotensin-converting enzyme inhibitor lisinopril. Whether this holds true for patients with hypertensive heart disease was addressed in this prospective, randomized, double-blind trial.
Methods and results: A total of 35 patients with primary hypertension, LVH, and LV diastolic dysfunction were treated with either lisinopril (n=18) or hydrochlorothiazide (HCTZ; n=17). At baseline and after 6 months, LV catheterization with endomyocardial biopsy, Doppler echocardiography with measurements of LV peak flow velocities during early filling and atrial contraction and isovolumic relaxation time, and 24-hour blood pressure monitoring were performed. Myocardial fibrosis was measured by LV collagen volume fraction and myocardial hydroxyproline concentration. With lisinopril, collagen volume fraction decreased from 6.9+/-0.6% to 6. 3+/-0.6% (P:<0.05 versus HCTZ) and myocardial hydroxyproline concentration from 9.9+/-0.3 to 8.3+/-0.4 microg/mg of LV dry weight (P:<0.00001 versus HCTZ); this was associated with an increase in the early filling and atrial contraction LV peak flow velocity ratio from 0.72+/-0.04 to 0.91+/-0.06 (P:<0.05 versus HCTZ) and a decrease in isovolumic relaxation time from 123+/-9 to 81+/-5 ms (P:<0.00002 versus HCTZ). Normalized blood pressure did not significantly change in either group. No LVH regression occurred in lisinopril-treated patients, whereas with HCTZ, myocyte diameter was reduced from 22. 1+/-0.6 to 20.7+/-0.7 microm (P:<0.01 versus lisinopril).
Conclusions: In patients with hypertensive heart disease, angiotensin-converting enzyme inhibition with lisinopril can regress myocardial fibrosis, irrespective of LVH regression, and it is accompanied by improved LV diastolic function.
Comment in
- Targeting pathological remodeling: concepts of cardioprotection and reparation.
Weber KT. Weber KT. Circulation. 2000 Sep 19;102(12):1342-5. doi: 10.1161/01.cir.102.12.1342. Circulation. 2000. PMID: 10993849 No abstract available.
Similar articles
- Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis.
Brilla CG, Matsubara L, Weber KT. Brilla CG, et al. Hypertension. 1996 Aug;28(2):269-75. doi: 10.1161/01.hyp.28.2.269. Hypertension. 1996. PMID: 8707393 - Nocturnal reduction of blood pressure and the antihypertensive response to a diuretic or angiotensin converting enzyme inhibitor in obese hypertensive patients. TROPHY Study Group.
Weir MR, Reisin E, Falkner B, Hutchinson HG, Sha L, Tuck ML. Weir MR, et al. Am J Hypertens. 1998 Aug;11(8 Pt 1):914-20. doi: 10.1016/s0895-7061(98)00087-9. Am J Hypertens. 1998. PMID: 9715782 Clinical Trial. - Cardioreparation with lisinopril in the management of hypertension and heart failure.
Weber KT, Brilla CG, Janicki JS. Weber KT, et al. Cardiology. 1991;79 Suppl 1:62-73. doi: 10.1159/000174908. Cardiology. 1991. PMID: 1655265 Review.
Cited by
- Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19.
Silva-Santos Y, Pagni RL, Gamon THM, de Azevedo MSP, Bielavsky M, Darido MLG, de Oliveira DBL, de Souza EE, Wrenger C, Durigon EL, Luvizotto MCR, Ackerman HC, Marinho CRF, Epiphanio S, Carvalho LJM. Silva-Santos Y, et al. Front Pharmacol. 2024 Jul 12;15:1414406. doi: 10.3389/fphar.2024.1414406. eCollection 2024. Front Pharmacol. 2024. PMID: 39070798 Free PMC article. - Remote myocardial fibrosis predicts adverse outcome in patients with myocardial infarction on clinical cardiovascular magnetic resonance imaging.
Black N, Bradley J, Schelbert EB, Bonnett LJ, Lewis GA, Lagan J, Orsborne C, Brown PF, Soltani F, Fröjdh F, Ugander M, Wong TC, Fukui M, Cavalcante JL, Naish JH, Williams SG, McDonagh T, Schmitt M, Miller CA. Black N, et al. J Cardiovasc Magn Reson. 2024 Jul 23;26(2):101064. doi: 10.1016/j.jocmr.2024.101064. Online ahead of print. J Cardiovasc Magn Reson. 2024. PMID: 39053856 Free PMC article. - Preventive and Therapeutic Effects of Crocetin in Rats with Heart Failure.
Ma R, Li S, Mo Q, Chen X, Liang Y, Hu T, Hu H, He B, Li R, Kou J, Yu B. Ma R, et al. Pharmaceuticals (Basel). 2024 Apr 12;17(4):496. doi: 10.3390/ph17040496. Pharmaceuticals (Basel). 2024. PMID: 38675456 Free PMC article. - Hitting the Target! Challenges and Opportunities for TGF-β Inhibition for the Treatment of Cardiac fibrosis.
Vistnes M. Vistnes M. Pharmaceuticals (Basel). 2024 Feb 20;17(3):267. doi: 10.3390/ph17030267. Pharmaceuticals (Basel). 2024. PMID: 38543053 Free PMC article. Review. - The impact of image and performance enhancing drugs on atrial structure and function in resistance trained individuals.
Place F, Carpenter H, Morrison BN, Chester N, Cooper R, Stansfield BN, George KP, Oxborough D. Place F, et al. Echo Res Pract. 2023 Dec 6;10(1):19. doi: 10.1186/s44156-023-00031-y. Echo Res Pract. 2023. PMID: 38053157 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical